Physician profile
Amy C Murphy
NPI 1780627836
$12,146.88
in general payments reported to CMS, 2019-2025
62 companies · $1,910 in 2025
The $1,910 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,293 · 2020: $1,653 · 2021: $2,169 · 2022: $1,333 · 2023: $1,638 · 2024: $2,149 · 2025: $1,910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,698.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,698.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,454.26 | 2019-2025 | |
| Novo Nordisk INC | $994.14 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $785.83 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $680.27 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $524.37 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $512.72 | 2019-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $500.89 | 2019-2025 | |
| Glaxosmithkline, LLC. | $455.17 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $450.82 | 2019-2025 | Otezla, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $427.56 | 2019-2024 | Belsomra, Steglatro, Gardasil 9 |
| Astellas Pharma US INC | $403.60 | 2021-2025 | Veozah |
| Abbott Laboratories | $371.76 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $340.59 | 2019-2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $329.64 | 2022-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $287.09 | 2023-2024 | Qelbree, Qelbree |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.